Dream Team Clinical Trials
The Dream Team has planned 10 innovative clinical trials designed to explore new approaches to combine targeted therapies and immunotherapies. These clinical trials will test different strategies to maximally inhibit KRAS signaling and enhance tumor cell death in KRAS-mutant lung cancers.
One clinical trial currently enrolling patients is an open-label, two-part, phase Ib/II study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the MEK inhibitor trametinib and the BCl2-family inhibitor navitoclax (ABT-263) in combination in subjects with KRAS mutation-positive advanced solid tumors.
We will update this page with links to additional clinical trials as they open at hospitals across the country.